SIGA Technologies
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, SIGA Technologies sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
SIGA Technologies: 8 sponsored US clinical trials, none currently recruiting.
SIGA Technologies sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 4 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Smallpox, with 1 trials.
Upper-quartile sponsor footprint
SIGA Technologies sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
8 total, page 1 of 1
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
NCT04957485
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
NCT04485039
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
NCT04971109
Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
NCT04392739
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
NCT02474589
Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
NCT00907803
Phase I Trial of an Investigational Small Pox Medication
NCT00728689
Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers
NCT00431951
How the SIGA Technologies archive is shaped
8 indexed studies, none listed as recruiting (0% open); 7 completed (88%).
Phase mix: 4 late (III/IV) vs 4 early (I/II) (balanced across stages).
Top condition: Smallpox (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
SIGA Technologies: archived-pipeline peers nationwide
Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
SIGA Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 archived trials
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this SIGA Technologies page
8 registered trials is a research-attention snapshot, not an endorsement of SIGA Technologies or any single study.
- None of SIGA Technologies's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Smallpox is the condition SIGA Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Smallpox trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
SIGA Technologies pipeline card: 8 registered trials from official public datasets.Report a data error.